HAEMATO AG
HAEMATO AG: Q1 2015: Sales of EUR 45.16 million, net profit EUR 1.23 million
HAEMATO AG / Key word(s): Quarter Results/Development of Sales Corporate News of HAEMATO AG: In the first three months of 2015, HAEMATO AG, Berlin (ISIN: DE0006190705), achieved IFRS-Group sales of EUR 45.16 million (prior-year period: EUR 53.69 million) and net profit for the period of EUR 1.23 million (prior-year period: EUR 2.90 million). “Like in the second half of 2014, sales and net profit of the HAEMATO Group of the first quarter 2015 were below the level of the previous year period. From July 2014 to April 2015 tightenings in the pharmaceutical regulations led to a considerable reduction of the stock turn rate. For the period from May to December 2015 we are confident to reach good results. In good time to the lifting of the tightenings of the pharmaceutical regulations we have doubled our production capacities. Thus in the second half of 2015 we will catch up which was achieved less in the first quarter 2015”, so Dr. Christian Pahl, Member of the Management Board of HAEMATO AG. About HAEMATO: HAEMATO AG, founded in 1993, is a pharmaceutical company, listed on the Frankfurt Stock Exchange in the Entry Standard (Open Market) and is based in Schönefeld, Germany. The focus of the business activities lies on the growth markets of patent free and patent protected medicinal products. Focal points are therapies with cancer, HIV and other chronic diseases. Contact: HAEMATO AG, Investor Relations Telefon: +49 (0)30 897 30 86 70 ir@haemato.de 2015-05-26 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
361591 2015-05-26 |